reason report
bottom line substanti higher convict
fundament polici risk meaning overblown rais pt
management meet hq feb part rebat
propos look like delay later given
drug compani part plan perceiv timelin aggress
lawmak see polit risk premium increas senior
ahead elect even part rebat chang
well prepar mitig downsid even competit upsid amid
disrupt discuss point bipartisan support extens
hipf moratorium current expect
view even hipf return consensu floor
normal growth guidanc achiev given manag express
commit normal ep growth guidanc rang
return top game moat built brand
multi channel distribut integr clinic platform
landscap compris vertic integr
hold even lower scale cfo focus intellig
capit deploy enabl partnership medicaid build look pois
organ pt contempl price-to-earnings
averag reiter ep multipl catalyst
propos look like delay
post elect presid seek tweetabl populist win
ahead elect concern part plan operation
drug compani impact dramat domest part
price chang market payor segment
perceiv polit risk hous democrat lawmak
premium increas senior ahead elect make
like view kick road ceo bruce
broussard see propos hh rebat chang pois drive unwant
behavior reward high util brand drug higher drug
compani margin healthier senior govern bear
brunt fiscal part plan seen arbit power
move dollar across winner loser smooth disrupt
prepar mitig downsid risk part
rebat chang could even turn opportun
return part domin amid disrupt
contempl regulatori competit scenario june bid
design mitig downsid includ potenti advers
select appropri level conservat embed given
lower oper profit exposur segment
price-to-earnings average
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu billion ep ep
quarterli number may sum total due round
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
discuss point bipartisan support extens hipf
moratorium current expect
top legisl prioriti per chief corpor affair offic
heidi marguli vice-president feder affair doug stoss would huge
medicar seen unlik proceed legisl beyond
rhetor big concern investor comfort also
hear corpor affair much less like proceed
legisl conclus like remain rhetor democrat
manag appear confid fundament domin
medicar advantag return acceler growth rate
proof point sustain even amid volatil hipf
polici growth came competitor rather
ff view share gain driven brand multi
channel distribut integr tech enabl clinic platform
richer benefit cfo brian kane point lack correl
membership growth hipf offer growth
rate polici tailwind current plan friendli
offer potenti membership growth margin
expans enabl requir invest technolog
primari care low margin guid
expand grow membership
smart capit deploy overcom scale challeng amid
new landscap compris vertic
integr hold even lower scale
 cfo strateg focu medicar advantag intellig
capit deploy enabl thought partnership strategi
senior focus primari deliveri key focu across
build buy partner strategi center today across
state success mp retail clinic pilot kc built
full servic chronic care manag platform physician
pharmacist could expand retail knd
invest offer opportun disrupt valu base
medicaid strategi like organ manag
optimist futur state determin need integr
medicaid attract dual market achiev organ
view june tx award like go favor heel
success fl state wide award
catalyst abound pt contempl price-to-earnings
averag reiter ep view
consensu floor assum return obamacar hipf
upcom catalyst includ feb senat hear drug price
pharma ceo investor day end comment period
part rebat propos april april final rate notic
look pois nice feb advanc notic may report
june tx medicaid award like legisl extens hipf
moratorium
substanti higher convict fundament basi see polici risk
meaning overblown rais pt manag meet hq feb
polici downsid risk overblown part rebat propos look like
delay post elect given biopharma part plan perceiv
timelin aggress lawmak see inevit premium increas polit risk ahead
elect link link even part rebat chang move propos
prepar address june bid mitig downsid also look
upsid reclaim domin competit posit amid disrupt
impress day bipartisan support hipf moratorium
extend medicar seen unlik proceed legisl beyond
rhetor view even hipf return consensu floor
normal growth guidanc achiev given manag express commit
return top game medicar advantag marketplac strong
competit moat built foundat consum market brand distribut
landscap compris vertic integr hold
even lower scale cfo strateg focu medicar advantag
intellig capit deploy enabl thought partnership strategi
manag optimist futur state determin need integr medicaid
attract dual market achiev organ view june tx award
like go favor heel success fl state wide award
pt contempl price-to-earnings averag reiter
ep view consensu floor assum return obamacar
upcom catalyst includ feb senat hear drug price investor day end
comment period part rebat propos april april final rate notic
look pois nice feb advanc notic may report june tx medicaid award
like legisl extens hipf moratorium
pleasur visit hq investor yesterday fulsom
discuss senior member manag team led ceo bruce broussard cfo
touch variou oper corpor affair strategi financi outlook
part rebat propos look like delay post-elect
presid seek tweetabl populist win ahead elect concern part
plan operation drug compani impact dramat domest part
price chang market payor segment perceiv polit risk
hous democrat lawmak premium increas senior ahead
elect make like view kick road link link
ceo bruce broussard eloqu describ propos hh rebat chang pois
drive unwant behavior reward high util brand drug even higher potenti
margin drug compani healthier senior govern see brunt higher
premium spend part plan seen arbit power move dollar
across winner loser smooth disrupt
perceiv risk premium increas ahead elect caus concern among
lawmak ahead elect like delay even
hh analysi impact beneficiari premium variou actuari scenario
democrat leadership oppos hh rule ground increas premium
among part plan expect part drug rebat chang drive premium increas
well prepar mitig downsid risk part rebat chang
could even turn opportun return part domin amid
even part rebat chang move propos contempl
regulatori competit scenario june bid design mitig downsid includ
potenti advers select appropri level conservat embed given
lower oper profit exposur segment manag even contempl potenti
return leadership posit amid rebat driven disrupt price sensit
senior shop activ sell season adopt upsid reclaim
domin competit posit amid disrupt
speaker hous nanci pelosi come strong opposit hh planth trump administr rebat propos put major medicar beneficiari risk higher premium total out-of-pocket cost put american taxpay hook hundr billion dollarsn pelosi press releasewithout comment much specif rebat propos obvious would major chang way pdp pd program work rebat discount go point sale perspect would rais premium broader popul think creat disrupt marketplac think think broadli think talk sort creat differ valu prop irrespect rebat go someth think obvious potenti partner well rebat chang materi hard say whether implement one thing mind potenti advers select could way product price given fact idea negoti best rebat could creat risk pool imbalanc question kind incent creat pbm negoti discount someth think industri policymak need think wherev polici goe prepar feel good broadli posit bruce broussard presid ceo director humana inc call inc
manag look bring innov regain part domin disrupt rebat
chang may even potenti posit catalyst share gain
view even hipf return consensu
floor normal growth guidanc achiev given
manag express commit normal ep
discuss point bipartisan support extens hipf moratorium
current expect top legisl prioriti per chief corpor affair
offic heidi marguli vice-president feder affair doug stoss would huge catalyst
acknowledg pdp plan becom commod evidenc other experienc signific declin pdp enrol recent complet price leader take share recal pioneer pdp market introduct low price co-brand plan wal-mart other industri imit plan take time intend stay competit work altern chang valu proposit impact market think part market evolut result polici rebat counter one exampl also innov program come cmmi give detail go construct believ combin studi market certain need mayb littl broader part need price point view packag servic within see time think market run cours commodit chang actual offer refresh valu proposit want use chang actual way enhanc valu proposit outsid run price bruce broussard presid ceo director inc call inc
extens hipf moratorium top lobbi legisl prioriti
even absent hipf moratorium manag commit
consist ep growth normal guidanc
hipf headwind fallen bottom line
comfort hear ceo consist ep growth sharehold
keen focu smooth benefit volatil senior cost effici trend
bender delay discretionari spend capit deploy
hipf headwind obvious correl membership growth year
past histori suggest market distribut nois around aet deal plan
divestitur op better predictor
pharma opportun new rebat world also risk
margin could expand new rebat world pharma like pass
upsid convers on-going part plan includ drug compani
similarli opportun also exist pharma compani data analyt rem risk
remain far impact intern price within payor segment
medicaid best price va/dod also remain unclear two differ price structur
maintain commerci medicar even absent legisl action commerci
evid industri whole invest benefit member great part due hif moratorium believ return hif neg impact senior across nation form reduc benefit and/or higher premium accordingli work partner urg congress take legisl action repeal hif beyond recogn sens urgenc given rapidli approach deadlin submit bid medicar advantag offer bruce broussard presid ceo director humana inc call inc
medicar seen unlik proceed legisl beyond
big concern investor comfort also hear corpor affair
much less like proceed legisl conclus like remain rhetor
medicar unlik legisl action proceed beyond rhetor congression
svb leerink analysi recent polit news flow kff
higher likelihood passedlow likelihood passedmedicar fixesprotect pre-exist conditionsdiscourag use less expens less comprehens insur plansreimplement individu mandat flavor singl nation health plan public plan offer exchang medicar buy-in optionmost like implement via public/priv partnership medicar advantag medicar challeng implementcost would exorbitantli high medicar would shift annual privat employ spend feder govern doubl project feder budget deficit-sen sander bill project cost first year full implement unlik pass republican senat face presidenti vetomoder democrat realiz need implement fix medicar need thing doabl arent pie sky -sen diann feinstein d-ca let build gain made afford act let also address thing republican undermin market -rep ami bera d-elk grove inc
manag express confid return former domin medicar
advantag marketplac retail increas success dual
target focu group
heavili focus market
manag see acceler return growth sustain even amid
volatil hipf polici growth came competitor rather
ff chang meaning prior year view share gain
driven distribut clinic platform richer benefit cfo brian kane point
lack correl membership growth hipf offer better
growth market forc despit return hipf captiv broker sale
forc market point complement extern broker relationship align
commiss broader retail primari care clinic key driver return growth
market share gain
strong competit moat differenti integr clinic platform
like see rate polici tailwind final rate pois exceed initi
rate polici tailwind current plan friendli offer potenti
membership growth margin expans enabl requir invest
total changeyoy end focus five area influenc primari care home pharmaci behavior health andsoci determin continu make advanc five area like tobriefli touch primari care conviva continu make oper improv expect joint ventur allianc clinic major payor-agnost includ twopartn primari care clinic insid walgreen store experienc posit result annual elect period humana membership grew clinic exclud matur conviva clinic bruce broussard presid ceo director humana inc call inc
technolog primari care neg surpris perceiv advanc rate notic
optim better final rate plan friendli
low margin guid expand grow
membership though new member year oper margin contribut
rather achiev peak margin year custom acquisit
manag seem optimist final rate notic due april
smart capit deploy overcom scale challeng amid new
landscap compris vertic integr hold
even lower scale cfo strateg focu medicar advantag
intellig capit deploy enabl thought partnership strategi
advancer noticefin advancenotic estimatesactu noticeeffect growth code intens model data group waiver payment averag chang revenu advanc notic averag chang inc
intellig capit deploy allow compet
strateg focu clinic integr across primari care technolog enabl data
analyt health social determin go forward rule chang
includ virtual health hospic within bundl play well hum focu nurs
assist virtual primari hospic invest link
expect leverag network part assist telehealth though
intent build virtual cafe technolog platform
strateg focu clinic integr reduc friction point
integr senior focus primari deliveri key strateg focu across build buy
partner strategi center today across state success retail clinic
pilot kc built full-servic chronic care manag platform physician
pharmacist reson particularli well singl male senior demograph could
emul market retail partner physician group valu
base care focu scarc asset still consid option acquisit select
market orlando fpg deal invest privat equiti back primari care
ventur includ oakstreet iora also offer smart capit approach toward scale
employ variou model integr value-bas primari deliveri
knd invest offer opportun disrupt valu base link
geograph overlap book pois offer path disrupt health
toward chronic manag ff therapi model pdgm reimburs
chang act anoth catalyst
capit effici partnership drive primari deliveryw alway look way get doctor take risk us might involv put organ clinic call pipc partner primari might invest variou partnership folk like oak street iora jen might wholli look buy asset exist certainli see us continu invest nyth realli could advanc integr care deliveri strategi engag member product way engag provid value-ad way extent opportun around home clinic capabl look expand brian kane cfo inc competitor confer humana inc
knd acquisit set disrupt toward value-bas ff
manag optimist futur state determin need integr medicaid
attract dual market achiev organ view june tx award
like go favor heel success fl state wide award
serv member fl
ep upsid addit member fl
regard home establish independ home health compani join kindr curothat provid signific overlap medicar advantag busi implement care andpay model orient patient multipl chronic condit five pilot market optim ourabl exchang key medic histori kindr use inform home healthadmiss process inform patient treatment plan deploy evidence-bas disease-specif careplan identifi priorit impact clinic intervent addit kindr select care base electron medic record practicemanag system home health hospic begin implement system acceler abil proactiv identifi key clinic intervent improv revenu captur andbusi qualiti report bruce broussard presid ceo director humana inc callcurr membershipaddit total membership estimatesnew member expect pmpm profit estim upsid upsid new region fl inc
tx contract
mm member strong tricar north south contract built foundat hum
integr behavior pharmaci primari platform also offer potenti
underappreci upsid estim beyond
employ segment also also view opportun growth chri
hunter leadership rather run-off strategi true self-fund
aso stop loss segment attack recent employ broker feedback
suggest dramat improv percept hum commerci offer link
 nfp bcb led rate price
follow highmark
ci led rate benefit design
follow nfp bcb
note rank scale best worst
note rank scale best worst
membership estim revenu pmpm mmtotal cvh hipantmunhhighmarknfp bcbshumbrok rate carrier best cvh unhnfp bcbscihumbrok rate carrier benefit best inc
reiter estim above-consensu ep
contempl retail margin expand still offer opportun
target link
ep guid within upper end consensu
manag expect grow ep commit lt ep growth even
without hipf benefit
ep yoy growth modestli consensu
growth low end normal growth guidanc see estim
achiev even return hipf substanti upsid hipf
moratorium legisl extend seem possibl
pt contempl price-to-earnings averag
unchang ep view consensu
floor assum return obamacar hipf
offer state art technolog enabl medicar advantag plan clinic
integr platform across digit health data power ai ml pure play
clinic integr medicar advantag privat back health plan devot recent
valu whop link would suggest potenti meaning multipl
expans overhang hipf part price chang rebat elimin pass
devot reportedli valu last round
cnbc report devot rais mm valuationdevot health insur start-up target senior valu billion peopl familiar matter told cnbc rais million fresh capit earlier week sourc ask name valuat disclos devot big rais valuat expect given background team capit requir new insur busi park brother previous help build athenahealth todd co-found castlight ed also sit board also reflect fact devot hot space attract investor attent bright rais million number ventur capit firm oscar recent net million alphabet expand new busi segment includ cnbc articl humana inc
trade ep
upcom catalyst multipl expans includ feb senat hear drug price
pharma ceo investor day end comment period part rebat
propos april april final rate notic look pois nice feb advanc
notic may report june tx medicaid award like legisl extens hipf
moratorium
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yield adequ return
capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings averag ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base absolut price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
price target base price-to-earnings averag ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
integr regulatori risk across merg ci esrx
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans price target base case
ep estim
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
pt contempl price-to-earnings consensu ep
price-to-earnings ep expect synergi across administr effici
retail steerag aet member benefit design chang floor rebat reduct
store base distribut part polici drive upsid estim also
multipl expans pt
underwrit risk aet asset trade peak margin commerci fulli
insur though medacorp commerci broker price survey give us confid
price environ remain appropri hard offer flat even potenti
modestli expand underwrit margin risk potenti futur margin compress
aet health insur even meaning given associ neg impact
debt ebitda load compani need focus debt
pay next month departur shawn guertin aet cfo
slate becom cfo make us less confid price postur
health insur book commenc new bulk compet
share gain commerci medicar advantag market
macroeconom risk risk macroeconom downturn higher
defens pbm sub sector given cyclic correl retail front store
sale employ data
regulatori risk convinc pbm add valu earn
low probabl threat potenti drug manufactur rebat elimin off-set
new busi model includ administr fee and/or perform guarante
expos pbm retail pharmaci busi compar
player pbm risk
execut integr risk face greater risk well given integr
pbm broader organ also transform agenda around
build retail front model amid risk leverag balanc sheet
e-commerce/amzn greater exposur eros sale on-line
channel well given exposur retail front store retail pharmaci e-
commerc though larg price retail multipl expect less like
pursu agenda becom pbm given associ integr clinic evid
base treatment guidelin integr provid network domin captiv pbm
model mega deal
remain posit reiter op rate month pt
contempl price-to-earnings averag ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yet yield adequ
return capit
pt reflect price-to-earnings ep
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
base post month turnaround rate outperform pt
contempl price-to-earnings averag ep
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
averag cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
averag ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
humana inc incom mm except per servic oper invest expenseshealth care oper oper incom net share dilut earn per ep growth inc
health enrol enrol thousand total medicar medicar stand-alon hmo medic membership govern enrol thousand commerci fulli insur commerci fulli life post specialti inc
